AuditorJul 8, 2026, 04:27 PM
Oncolytics Biotech Changes Auditor to Baker Tilly
AI Summary
Oncolytics Biotech Inc. announced a change in its independent registered public accounting firm. Effective July 6, 2026, the company disengaged Ernst & Young LLP (EY) and engaged Baker Tilly US, LLP for the 2026 fiscal year, citing corporate restructuring as the reason. The company confirmed there were no disagreements with EY on any accounting or auditing matters, although EY's previous reports included a going concern explanatory paragraph. There were also no prior consultations with Baker Tilly on accounting principles or audit opinions.
Key Highlights
- Oncolytics Biotech Inc. disengaged Ernst & Young LLP (EY) as its independent registered public accounting firm.
- The change was effective July 6, 2026, due to the Company’s corporate restructuring.
- Baker Tilly US, LLP was engaged as the new independent registered public accounting firm for the 2026 fiscal year.
- EY's reports for fiscal years 2024 and 2025 included an explanatory paragraph regarding the Company's ability to continue as a going concern.
- There were no disagreements with EY on accounting principles, financial statement disclosure, or auditing scope.
- Neither the Company nor Baker Tilly consulted on accounting principles or audit opinions prior to the engagement.
Price Impact
More from ONCY